All In Biotech

NDA 013174 · Advanz Pharma

Dyrenium

Triamterene · Oral · Potassium-sparing Diuretic

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Feb 28, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1964

Aug 10, 1964

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

2 Phase 3, 1 recruiting

FAERS reports

7,328

4,003 serious, 414 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Warnings Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving Dyrenium, when dosages are changed or with any illness that may influence renal function. WARNINGS Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including Dyrenium. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected...

What it is approved for

From the label in effect Dec 5, 2024.

INDICATIONS AND USAGE Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 10, 1964 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • DYRENIUM · TRIAMTERENE 100MG · CAPSULE, ORAL · Prescription · TE AB
  • DYRENIUM · TRIAMTERENE 50MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Triamterene" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease479
  • fatigue476
  • drug ineffective453
  • pain439
  • nausea420
  • diarrhoea405
  • dyspnoea348
  • dizziness345
  • renal failure329
  • headache327
  • arthralgia314
  • acute kidney injury308

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004144
2005178
2006154
2007133
2008152
2009237
2010323
2011295
2012312
2013280
2014384
2015538
2016487
2017475
2018664
2019599
2020405
2021364
2022308
2023237
2024237
2025225
2026197

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dyrenium (Triamterene)

2024 spending

$262K

Beneficiaries

53

229 claims

Per beneficiary

$4,943

$13.40 per unit

View as table
YearSpending
2020$797,218
2021$477,783
2022$322,966
2023$283,315
2024$261,979

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 167 on PubMed

Sponsor: Advanz Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.